A more comprehensive understanding of the specific roles of both the innate and adaptive immune systems throughout the progression of AD pathology, especially during the tau phase, is likely to facilitate the development of novel therapeutic strategies for both the pre-clinical and clinically symptomatic phases of AD. The gene discussed is MAPT; the disease is Alzheimer disease.